Scholars Central

Conference abstractPublished 24 Oct 2016

Development of novel targeted therapies for triple negative breast cancer: Targeting EF2-kinase

Authors: Bulent Ozpolat

University of Texas, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Triple-negative breast cancer refers to any breast cancer which is clinically characterized as more aggressive and less responsive to standard treatments, and is associated with poor overall patient prognosis. Therefore, there is an urgent need to develop effective and safe therapies against triple negative breast cancer due to poor prognosis and lack of targeted therapies. Recently, we found that EF2-Kinase (EF2K) is significantly overexpressed in breast cancer cell lines compared with normal breast epithelium and its expression is associated with poor patient overall survival. However, its regulation and the role in breast cancer progression and tumorigenesis are not known. We demonstrated, for the first time, that inhibition of EF2K blocked proliferation, colony formation and invasion and tumorigenesis of TNBC tumors. We also discovered that FOXM1 and a microRNA directly binds and regulates EF2K gene expression and targeting of these molecules recapitulates the effects of EF2K targeting inhibit proliferation, invasion migration and tumor growth in TNBC models. We demonstrated blocked tumor growth tumor xenografts and significantly enhanced the in vivo efficacy of chemotherapy. Inhibition of FOXM1-miRNA/eEF2K axis significantly reduced Src/Fak/Paxillin, IGF-1R, PI3K/Akt/mTOR, cyclinD1, c-myc, HIF1 alpha and VEGF and induced significant apoptosis in tumors. Overall, our studies suggest that EF2-Kinase plays an important role in TNBC tumorigenesis and progression and EF2K targeted therapies provide the proof of concept for translation into Phase-I clinical trials in patients.

Subjects

Toxicology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Toxicology
  • SubjectToxicology
  • BylineArticles whose byline prints “Bulent Ozpolat”